Ota T, Akaza H, Hattori K, Uchida K
Department of Urology, Institute of Clinical Medicine, University of Tsukuba.
Nihon Hinyokika Gakkai Zasshi. 1997 Oct;88(10):868-73. doi: 10.5980/jpnjurol1989.88.868.
We previously reported that the average tumor growth speed estimated from clinical findings may be useful as a prognostic factor to determine the stage progression in superficial bladder cancer. Here, we examined the relationship between the dynamic estimation based on the average tumor growth speed and the static estimation based on the biological proliferative activity determined from bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) indices in superficial bladder cancer.
The subjects were 11 patients with recurrent superficial bladder cancer. The tumor growth speed was calculated by dividing all tumor volume at a certain recurrence episode by the duration until the recurrence. And then, the average tumor growth speed was determined individually by calculating mean tumor growth speed for all recurrence episodes. BrdU and PCNA indices were investigated by immunohistochemical staining.
There was a significant correlation between the average tumor growth speed and indices of PCNA and BrdU were statistically (Spearmen's rank correlation test; between the growth speed and PCNA index: p = 0.85, p < 0.01; between the average tumor growth speed and BrdU index: p = 0.71, p < 0.05; between BrdU index and PCNA index: p = 0.77, p < 0.05). The average tumor growth speed which was calculated based on clinical findings reflected the biological proliferative activities such as BrdU and PCNA indices. Furthermore, the values of all indices were higher in the invasive than in the non-invasive cases.
These findings suggest that the average tumor growth speed as the dynamic estimation is an important prognostic factor to determine stage progression in superficial bladder cancer.
我们之前报道过，根据临床检查结果估算的平均肿瘤生长速度，可能作为判断浅表性膀胱癌分期进展的一个预后因素。在此，我们研究了基于平均肿瘤生长速度的动态评估与基于溴脱氧尿苷（BrdU）和增殖细胞核抗原（PCNA）指数所确定的生物学增殖活性的静态评估之间在浅表性膀胱癌中的关系。
研究对象为11例复发性浅表性膀胱癌患者。肿瘤生长速度通过将某一复发阶段的所有肿瘤体积除以直至复发的持续时间来计算。然后，通过计算所有复发阶段的平均肿瘤生长速度来分别确定平均肿瘤生长速度。通过免疫组织化学染色研究BrdU和PCNA指数。
平均肿瘤生长速度与PCNA指数以及BrdU指数之间存在显著相关性（Spearman秩相关检验；生长速度与PCNA指数之间：p = 0.85，p < 0.01；平均肿瘤生长速度与BrdU指数之间：p = 0.71，p < 0.05；BrdU指数与PCNA指数之间：p = 0.77，p < 0.05）。基于临床检查结果计算出的平均肿瘤生长速度反映了诸如BrdU和PCNA指数等生物学增殖活性。此外，所有指数的值在浸润性病例中高于非浸润性病例。
这些发现表明，作为动态评估的平均肿瘤生长速度是判断浅表性膀胱癌分期进展的一个重要预后因素。
